Repository logo
 

IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Joustra, Sjoerd D 
Roelfsema, Ferdinand 
van Trotsenburg, AS Paul 
Schneider, Harald J 
Kosilek, Robert P 

Abstract

CONTEXT: The X-linked immunoglobulin superfamily, member 1 (IGSF1), gene is highly expressed in the hypothalamus and in pituitary cells of the POU1F1 lineage. Human loss-of-function mutations in IGSF1 cause central hypothyroidism, hypoprolactinemia, and macroorchidism. Additionally, most affected adults exhibit higher than average IGF-1 levels and anecdotal reports describe acromegaloid features in older subjects. However, somatotrope function has not yet been formally evaluated in this condition. OBJECTIVE: We aimed to evaluate the role of IGSF1 in human and murine somatotrope function. PATIENTS, DESIGN, AND SETTING: We evaluated 21 adult males harboring hemizygous IGSF1 loss-of-function mutations for features of GH excess, in an academic clinical setting. MAIN OUTCOME MEASURES: We compared biochemical and tissue markers of GH excess in patients and controls, including 24-hour GH profile studies in 7 patients. Parallel studies were undertaken in male Igsf1-deficient mice and wild-type littermates. RESULTS: IGSF1-deficient adult male patients demonstrated acromegaloid facial features with increased head circumference as well as increased finger soft-tissue thickness. Median serum IGF-1 concentrations were elevated, and 24-hour GH profile studies confirmed 2- to 3-fold increased median basal, pulsatile, and total GH secretion. Male Igsf1-deficient mice also demonstrated features of GH excess with increased lean mass, organ size, and skeletal dimensions and elevated mean circulating IGF-1 and pituitary GH levels. CONCLUSIONS: We demonstrate somatotrope neurosecretory hyperfunction in IGSF1-deficient humans and mice. These observations define a hitherto uncharacterized role for IGSF1 in somatotropes and indicate that patients with IGSF1 mutations should be evaluated for long-term consequences of increased GH exposure.

Description

Keywords

IGSF1, congenital hypopituitarism, growth hormone, pituitary, Adult, Aged, Aged, 80 and over, Animals, Growth Hormone, Humans, Immunoglobulins, Insulin-Like Growth Factor I, Intercellular Signaling Peptides and Proteins, Male, Membrane Proteins, Mice, Middle Aged, Neurosecretion, Somatotrophs

Journal Title

J Clin Endocrinol Metab

Conference Name

Journal ISSN

0021-972X
1945-7197

Volume Title

105

Publisher

The Endocrine Society

Rights

All rights reserved
Sponsorship
Wellcome Trust (100585/Z/12/Z)
Medical Research Council (MC_UU_12012/5)
Wellcome Trust (208363/Z/17/Z)
MRC (MC_UU_00014/5)
Medical Research Council (MC_PC_12012)
: We acknowledge support from the Wellcome Trust to NS (100585/Z/12/A), GRW and JHDB (Strategic Award 101123/Z/13/A; Joint Investigator Awards 110140/Z/15/Z and 110141/Z/15/Z) and The National Institute for Health Research Biomedical Research Centre Cambridge (MG, NS). The Disease Model Core is supported by the UK MRC Metabolic Diseases Unit [MC_UU_00014/5] and the Wellcome Trust Major Award [208363/Z/17/Z]). PLT was funded by the UK MRC (U117562207). The Core biochemical Assay Laboratory is supported by MRC Metabolic Diseases Unit [MC_UU_00014/5]. DJB was supported by grants from the Canadian Institutes of Health Research (MOP-133557) and the Natural Sciences and Engineering Research Council of Canada (2015-05178).